You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,098,882


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,098,882 protect, and when does it expire?

Patent 10,098,882 protects RYKINDO and is included in one NDA.

This patent has thirty-six patent family members in fourteen countries.

Summary for Patent: 10,098,882
Title:Risperidone sustained release microsphere composition
Abstract:A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
Inventor(s):Sun Kaoxiang, Liang Rongcai, Wang Qilin, Wang Wenyan, Liu Wanhui, Li Youxin
Assignee:
Application Number:US15347365
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,098,882: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article delves into the details of United States Patent 10,098,882, focusing on its claims, scope, and the broader patent landscape.

Overview of the Patent

Patent Title and Description

United States Patent 10,098,882, titled "Risperidone Sustained Release Microsphere Formulation," pertains to a specific pharmaceutical formulation. The patent describes a microsphere formulation that includes risperidone or 9-hydroxy risperidone, or salts thereof, designed for sustained release[5].

Claims Analysis

Independent and Dependent Claims

The patent includes both independent and dependent claims. Independent claims define the broadest scope of the invention and are typically more general, while dependent claims narrow down the scope by adding specific limitations.

  • Independent Claims: These claims outline the core elements of the invention. For example, Claim 1 might describe the composition of the microsphere formulation, including the active ingredients and the sustained release mechanism.
  • Dependent Claims: These claims build upon the independent claims by adding additional features or limitations. For instance, Claim 2 might specify the size range of the microspheres or the particular excipients used.

Claim Language and Scope

The scope of the patent is heavily influenced by the language used in the claims. Metrics such as independent claim length and independent claim count can provide insights into the breadth of the patent. Generally, narrower claims with fewer words and fewer independent claims tend to have a more focused scope, which can be beneficial for avoiding litigation and ensuring clarity[3].

Patent Scope and Breadth

Measuring Patent Scope

Patent scope can be measured using various metrics, including independent claim length and count. These metrics help in understanding whether the patent claims are overly broad or narrowly defined.

  • Independent Claim Length: Shorter independent claims often indicate a more focused and narrower scope, which can be associated with higher grant probabilities and shorter examination processes[3].
  • Independent Claim Count: Fewer independent claims suggest a more streamlined and less complex invention, which can reduce the likelihood of disputes over patent validity.

Impact on Innovation and Litigation

The breadth of patent claims can significantly impact innovation and litigation costs. Overly broad patents can lead to increased licensing and litigation costs, potentially diminishing incentives for innovation. In contrast, narrower claims tend to provide clearer boundaries, reducing the risk of disputes and fostering a more innovative environment[3].

Patent Examination Process

Examination and Narrowing of Claims

The patent examination process often results in the narrowing of claims. This is because examiners may require additional specificity or limitations to ensure the claims are novel, non-obvious, and useful.

  • Changes During Examination: The examination process tends to narrow the scope of patent claims in terms of both claim length and claim count. Longer examination durations often result in more significant changes to the claims[3].

Patent Landscape and Prior Art

Global Dossier and International Search

To understand the patent landscape, it is essential to search for prior art globally. Tools like the Global Dossier and international patent databases (such as those provided by the European Patent Office, Japan Patent Office, and World Intellectual Property Organization) help in identifying related applications and prior art[1].

Common Citation Document (CCD)

The Common Citation Document (CCD) consolidates prior art cited by multiple patent offices, providing a comprehensive view of the prior art landscape for a specific invention. This tool is particularly useful for ensuring that the claims of the patent are novel and non-obvious[1].

Legal Considerations and Patent Eligibility

Section 101 of the Patent Act

Patent eligibility under Section 101 of the Patent Act is a critical legal consideration. The Supreme Court's "Alice" test is used to determine whether claims are directed to abstract ideas, laws of nature, or natural phenomena, which are not patentable. The test involves two steps: determining if the claims are directed to an abstract idea and, if so, whether the claims include elements that transform them into a patent-eligible application[2].

Case Law and Precedents

Cases such as Contour IP Holding LLC v. GoPro, Inc. highlight the importance of claim construction and the application of the "Alice" test. These precedents guide how courts interpret patent claims and determine their eligibility under Section 101[2].

Practical Implications for Inventors and Businesses

Conducting Preliminary Searches

Before filing a patent application, conducting a preliminary search using tools like the Patent Public Search and resources from Patent and Trademark Resource Centers (PTRCs) is crucial. This helps in identifying existing patents and prior art, ensuring the novelty and non-obviousness of the invention[1].

Drafting Clear and Narrow Claims

Drafting clear and narrowly defined claims can help in avoiding disputes and ensuring the patent is granted more quickly. This approach also aligns with the trends observed in patent examination processes, where narrower claims are more likely to be granted[3].

Key Takeaways

  • Patent Claims: Independent and dependent claims define the scope of the patent, with narrower claims generally being more beneficial.
  • Patent Scope: Metrics like independent claim length and count help in measuring the breadth of the patent.
  • Examination Process: The patent examination process often narrows the scope of claims to ensure novelty, non-obviousness, and usefulness.
  • Global Search: Conducting global searches using tools like the Global Dossier and CCD is essential for understanding the prior art landscape.
  • Legal Considerations: Ensuring patent eligibility under Section 101 and adhering to legal precedents like the "Alice" test are critical.

FAQs

What is the main subject of United States Patent 10,098,882?

The main subject of United States Patent 10,098,882 is a risperidone sustained release microsphere formulation.

How can the scope of a patent be measured?

The scope of a patent can be measured using metrics such as independent claim length and independent claim count. These metrics provide insights into the breadth and clarity of the patent claims.

What is the significance of the "Alice" test in patent law?

The "Alice" test is a two-step process used to determine whether patent claims are directed to abstract ideas, laws of nature, or natural phenomena, which are not patentable. It helps in ensuring that only eligible subject matter is patented.

Why is it important to conduct a global search for prior art?

Conducting a global search for prior art helps in identifying related applications and ensuring the novelty and non-obviousness of the invention. Tools like the Global Dossier and CCD facilitate this process.

How does the patent examination process affect the scope of patent claims?

The patent examination process often results in the narrowing of claims to ensure they meet the criteria of novelty, non-obviousness, and usefulness. This process can lead to shorter and more focused claims.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. CAFC - CONTOUR IP HOLDING LLC v. GOPRO, INC.: https://cafc.uscourts.gov/opinions-orders/22-1654.OPINION.9-9-2024_2381170.pdf
  3. SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. U.S. Department of Commerce - U.S. Patent and Trademark Office: https://www.commerce.gov/bureaus-and-offices/uspto
  5. Unified Patents Portal - US-10098882-B2: https://portal.unifiedpatents.com/patents/patent/US-10098882-B2

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,098,882

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-001 Jan 13, 2023 RX Yes No 10,098,882 ⤷  Subscribe Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Subscribe
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-002 Jan 13, 2023 RX Yes Yes 10,098,882 ⤷  Subscribe Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Subscribe
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-003 Jan 13, 2023 RX Yes No 10,098,882 ⤷  Subscribe Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.